# Stoke Therapeutics, Inc. (STOK) · Edgar & Edgarette company card

> Stoke Therapeutics (STOK) grew revenue 405% in FY2025 to $184 million, operating margin -11.2% against a -3.8% median for pharmaceutical preparations, equity 84.2% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1623526 · fiscal year ended 2025-12-31 · 4 audited years read · [page](https://www.pops4.com/boards/company/STOK) · [JSON](https://www.pops4.com/boards/company/STOK.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $184M |
| Revenue growth, 1 year | 404.5% |
| Revenue growth per year | 145.8% |
| Operating margin | -11.2% (prior year -277.3%) |
| Net margin | -3.7% |
| Operating cash flow | $46M |
| Capital spending | $670,000 |
| Free cash flow | $45M |
| Cash | $84M |
| Long-term debt | — |
| Total assets | $418M |
| Total equity | $352M |
| Equity ÷ assets | 84.2% |
| Return on equity | -2.0% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 5.29 (safe zone)
- Piotroski F: 5 of 9 (middling)
- Health Harbor boat: Weathered boat · two warning signs · filed auditor change in the last 12 months; operating loss: a margin of -11.2% in FY2025

## Edgarette's reading

Exposure: revenue $184.4M (FY2025). Experience: revenue up 404.5% on the year, up 145.8% a year over 3 years; operating margin -11.2%, up from -277.3%. Soundness: equity 84.2% of assets, return on equity -2.0%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $573.7M and $802.2M next year (method v4.1: its own 1-year record of growth weighed at 0% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $527.1M to $876.2M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -11.2% against a -3.8% median; growth 404.5% against 13.7%.

Range logged 2026-09-28, receipt 82428c7c5055f87f, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 4.01 Auditor change: 1, latest 2026-03-27 ([filing](https://www.sec.gov/Archives/edgar/data/1623526/000119312526129168/0001193125-26-129168-index.htm))
- Item 5.02 Director or officer change: 3, latest 2026-09-25 ([filing](https://www.sec.gov/Archives/edgar/data/1623526/000119312526402820/0001193125-26-402820-index.htm))

## Recent filings

- 10-Q · filed 2026-11-03 · [filing](https://www.sec.gov/Archives/edgar/data/1623526/000119312526445326/0001193125-26-445326-index.htm)
- 8-K · filed 2026-10-29 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1623526/000119312526437775/0001193125-26-437775-index.htm)
- 8-K · filed 2026-09-25 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1623526/000119312526402820/0001193125-26-402820-index.htm)
- 8-K · filed 2026-08-03 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1623526/000119312526330804/0001193125-26-330804-index.htm)
- 10-Q · filed 2026-08-03 · [filing](https://www.sec.gov/Archives/edgar/data/1623526/000119312526330557/0001193125-26-330557-index.htm)
- 8-K · filed 2026-08-03 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1623526/000119312526330537/0001193125-26-330537-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001623526.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1623526

## Cite

POPS4, Edgar & Edgarette: Stoke Therapeutics, Inc. (STOK) company card, from the company's own SEC filings, accessed 2026-11-12, https://www.pops4.com/boards/company/STOK. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.